Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
A Phase 2-B, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Encephalitis and Assess Markers of Disease
Grant
Overview
Affiliation
Overview
Awarded By
MASSACHUSETTS GENERAL HOSPITAL
Total Award Amount
26191.00
Direct Costs
18063.00
Sponsor Award Id
NN111
Affiliation
Contributor
Benjamin Jones
Principal Investigator
Frank Benesh
Investigator
John Rinker II
Investigator
Khurram Bashir
Investigator
Shruti Agnihotri
Investigator
William Meador
Investigator